Page 130 - 2019_11 Resto del Mondo-web
P. 130
X. Li et al.
E
Figure 6. (continued from the previous page) (E) Primary cells from patients with acute myeloid leukemia (AML) and normal human bone marrow mononuclear cells (BMMNC) from a single donor were treated with CUDC- 907 for 16 h and then subjected to alkaline comet assay analysis. Cells treated with 20 mM daunurubicin (DNR) for 4 h were used as a positive control. Representative images are shown. Data are presented as mean percent DNA in the tail from three replicate gels ± SEM. ***P<0.001. (F) U937 cells were treat- ed with CUDC-907 in the presence or absence of LY2603618 (LY), MK-1775 (MK), or hydrox- yurea (HU) for 24 h and then subjected to annexin V/propidium iodide (PI) staining and flow cytometry analyses. ***P<0.001. (G-I) MV4-11, U937 and MOLM-13 AML cell lines and two primary AML patients samples were treated with 0-100 nM CUDC-907 for 24 h. Total RNA was isolated and CHK1 (G), RRM1 (H), and Wee1 (I) transcripts were determined by real-time reverse transcriptase polymerase chain reaction (RT-PCR). *P<0.05, **P<0.01, and ***P<0.001. (J) Cells obtained from the MV4-11 xenografts, which were treated with a single dose of CUDC-907, were enriched for human cells. Then total RNA was isolated and real-time RT-PCR performed to determine CHK1, RRM1, and Wee1 transcripts. *P<0.05, **P<0.01, and ***P<0.001.
F
GH
IJ
2236
haematologica | 2019; 104(11)
